-
The agreement relates to CEVEC`s proprietary cell line (expression system) for the development, production and commercialization of proteins to treat the symptoms of Haemophilia patients
DREIEICH, Germany I July 1, 2015 I Biotest AG and CEVEC Pharmaceuticals GmbH (CEVEC) today announce that the companies have signed a licence agreement.
The agreement relates to CEVEC`s proprietary CAP® cells used for the production of recombinant proteins. Under the license agreement, Biotest utilizes CEVEC’s expression system for the development, production and commercialization of these proteins, for example to treat haemophilia patients.
“The technology from CEVEC with its cell expression system is an ideal complement for the future production of Biotest´s recombinant candidates in development” says Dr. Jörg Schüttrumpf, Senior Vice President Global Research Biotest.
About CEVEC’s Technology
CEVEC’s CAP® expression system comprises a comprehensive panel of glyco-optimized human suspension cell lines that differ in their glycosylation capabilities. The system enables the manufacture of difficult to express therapeutic glycoproteins, such as coagulation factors, with tailor-made or fully human glycosylation patterns.
About CEVEC:
Privately held CEVEC Pharmaceuticals GmbH is a global solution provider for the production of biopharmaceuticals based in Cologne, Germany. The Company’s technologies, including CAP®Go and CAP®GT are based on a unique human cell expression system.
The CAP®Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. The CAP®GT expression platform provides a fully scalable, regulatory endorsed production system for gene therapy vectors.
Research collaborations with international pharmaceutical and biotechnology partners followed by licensing agreements for the technology forms one revenue base for CEVEC. In addition, the Company provides contract manufacturing for the cGMP production in CAP®Go and CAP®GT cells.
SOURCE: Biotest
Post Views: 39
-
The agreement relates to CEVEC`s proprietary cell line (expression system) for the development, production and commercialization of proteins to treat the symptoms of Haemophilia patients
DREIEICH, Germany I July 1, 2015 I Biotest AG and CEVEC Pharmaceuticals GmbH (CEVEC) today announce that the companies have signed a licence agreement.
The agreement relates to CEVEC`s proprietary CAP® cells used for the production of recombinant proteins. Under the license agreement, Biotest utilizes CEVEC’s expression system for the development, production and commercialization of these proteins, for example to treat haemophilia patients.
“The technology from CEVEC with its cell expression system is an ideal complement for the future production of Biotest´s recombinant candidates in development” says Dr. Jörg Schüttrumpf, Senior Vice President Global Research Biotest.
About CEVEC’s Technology
CEVEC’s CAP® expression system comprises a comprehensive panel of glyco-optimized human suspension cell lines that differ in their glycosylation capabilities. The system enables the manufacture of difficult to express therapeutic glycoproteins, such as coagulation factors, with tailor-made or fully human glycosylation patterns.
About CEVEC:
Privately held CEVEC Pharmaceuticals GmbH is a global solution provider for the production of biopharmaceuticals based in Cologne, Germany. The Company’s technologies, including CAP®Go and CAP®GT are based on a unique human cell expression system.
The CAP®Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. The CAP®GT expression platform provides a fully scalable, regulatory endorsed production system for gene therapy vectors.
Research collaborations with international pharmaceutical and biotechnology partners followed by licensing agreements for the technology forms one revenue base for CEVEC. In addition, the Company provides contract manufacturing for the cGMP production in CAP®Go and CAP®GT cells.
SOURCE: Biotest
Post Views: 39
